Pfizer Inc. $PFE Shares Sold by Yelin Lapidot Holdings Management Ltd.

Yelin Lapidot Holdings Management Ltd. lowered its position in Pfizer Inc. (NYSE:PFE) by 23.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 215,000 shares of the biopharmaceutical company’s stock after selling 65,301 shares during the quarter. Pfizer accounts for 1.3% of Yelin Lapidot Holdings Management Ltd.’s investment portfolio, making the stock its 22nd biggest position. Yelin Lapidot Holdings Management Ltd.’s holdings in Pfizer were worth $6,037,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Kepler Cheuvreux Suisse SA purchased a new position in Pfizer in the third quarter valued at approximately $16,613,000. Mackenzie Financial Corp increased its position in shares of Pfizer by 119.6% in the third quarter. Mackenzie Financial Corp now owns 3,106,644 shares of the biopharmaceutical company’s stock worth $79,157,000 after acquiring an additional 1,691,773 shares in the last quarter. Penn Davis Mcfarland Inc. increased its position in shares of Pfizer by 50.9% in the fourth quarter. Penn Davis Mcfarland Inc. now owns 171,332 shares of the biopharmaceutical company’s stock worth $4,266,000 after acquiring an additional 57,777 shares in the last quarter. Ameriprise Financial Inc. raised its stake in shares of Pfizer by 48.2% in the 3rd quarter. Ameriprise Financial Inc. now owns 18,373,140 shares of the biopharmaceutical company’s stock valued at $468,174,000 after acquiring an additional 5,978,927 shares during the period. Finally, Danske Bank A S acquired a new position in shares of Pfizer during the 3rd quarter valued at $81,298,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently issued reports on PFE shares. Cantor Fitzgerald reiterated a “neutral” rating on shares of Pfizer in a report on Monday, June 1st. Bank of America lowered their target price on Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research note on Thursday, April 9th. Wall Street Zen upgraded Pfizer from a “hold” rating to a “buy” rating in a report on Sunday, June 21st. BMO Capital Markets reiterated an “outperform” rating on shares of Pfizer in a research note on Tuesday, June 23rd. Finally, Weiss Ratings upgraded shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, May 6th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $28.82.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The FDA expanded Pfizer’s Ibrance label for frontline maintenance in advanced breast cancer, a regulatory win that could support use of the drug and modestly improve Pfizer’s oncology revenue outlook. FDA expands Pfizer’s Ibrance label for frontline maintenance in advanced breast cancer
• Positive Sentiment: Pfizer declared its third-quarter 2026 dividend of $0.43 per share, reinforcing its appeal for income-focused investors and signaling continued confidence in cash generation. Pfizer Declares Third-Quarter 2026 Dividend
• Neutral Sentiment: Pfizer Ventures participated in a $62 million Series B for Oblenio Bio, highlighting the company’s broader innovation strategy, though the investment is not likely to have an immediate material impact on PFE shares. Oblenio Bio Closes $62 Million Series B…
• Neutral Sentiment: Pfizer halted a tafamidis bioequivalence study, which appears to be a study update rather than a major commercial setback, so the market reaction is likely limited unless further details emerge. Pfizer Halts Tafamidis Bioequivalence Study
• Negative Sentiment: Recent investor concern remains tied to Pfizer’s mixed oncology pipeline news, especially the failed Phase 3 sigvotatug vedotin lung cancer study, which has pressured sentiment around the company’s long-term growth narrative. Pfizer (PFE) Is Down 7.3% After Mixed Oncology Updates Reshape Its Long-Term Pipeline Narrative

Pfizer Price Performance

Shares of NYSE PFE opened at $24.27 on Monday. The business has a 50 day moving average price of $25.94 and a two-hundred day moving average price of $26.29. Pfizer Inc. has a fifty-two week low of $23.11 and a fifty-two week high of $28.75. The firm has a market cap of $138.35 billion, a PE ratio of 18.53 and a beta of 0.34. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, beating the consensus estimate of $0.72 by $0.03. The company had revenue of $14.45 billion during the quarter, compared to analysts’ expectations of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The business’s revenue was up 5.4% on a year-over-year basis. During the same period in the prior year, the business posted $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Sell-side analysts expect that Pfizer Inc. will post 2.99 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 7.1%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer’s dividend payout ratio (DPR) is currently 131.30%.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.